| Print
Insmed (INSM)
Common SharesNot yet a customer?
Low cost dealing from £1.50Choose from our range of SIPP, ISA and Dealing accounts
Find out moreThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Address
700 US Highway 202/206
Bridgewater
NJ
USA
08807
Telephone
+1 908 977-9900
Forecast key dates
Name | Key Date |
---|---|
Insmed Inc Third Quarter Earnings Conference Call for 2026 | 2026-10-30T08:00:00 |
Insmed Inc Third Quarter Earnings Results for 2026 | 2026-10-30T00:00:00 |
Insmed Inc Second Quarter Earnings Conference Call for 2026 | 2026-08-07T08:00:00 |
Insmed Inc Second Quarter Earnings Results for 2026 | 2026-08-07T00:00:00 |
Insmed Inc Annual General Meeting for 2026 | 2026-05-15T09:00:00 |
Insmed Inc First Quarter Earnings Conference Call for 2026 | 2026-05-08T08:00:00 |
Insmed Inc First Quarter Earnings Results for 2026 | 2026-05-08T00:00:00 |
Insmed Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-02-20T08:00:00 |
Insmed Inc Fourth Quarter Earnings Results for 2025 | 2026-02-20T00:00:00 |
Insmed Inc Annual Report for 2025 | 2026-02-20T00:00:00 |
Insmed Inc Third Quarter Earnings Conference Call for 2025 | 2025-10-30T08:00:00 |
Insmed Inc Third Quarter Earnings Results for 2025 | 2025-10-30T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.